Materiały źródłowe

• #1 Epidemiology of hidradenitis suppurativa – PubMed

  https://pubmed.ncbi.nlm.nih.gov/37696341/

  Hidradenitis suppurativa (HS) is a chronic, inflammatory, recurrent skin disease affecting hair follicles in predominantly intertriginous areas, characterized by deep, painful nodules and abscesses, fistulas, sinus tracts, and scarring. The estimated global prevalence of HS is highly variable, as revealed in a growing body of published literature, and ranges from 0.053% to 4.1%. […] In North American and European patients, HS is three times more common in women than men, whereas in South Korea and Japan, male predominance is found. The disease most frequently manifests itself between the ages of 18 and 29. […] We provide up-to-date evidence about the epidemiology, genetic and environmental risk factors, comorbidities, and quality of life of patients with HS. The divergence in HS frequency, possibly due to differences in populations and methodologies, remains to be explained in future worldwide studies.

• #2 Hidradenitis suppurativa: Pathogenesis, clinical features, and diagnosis – UpToDate

  https://www.uptodate.com/contents/hidradenitis-suppurativa-pathogenesis-clinical-features-and-diagnosis

  Hidradenitis suppurativa (HS; from the Greek hidros = sweat, and aden = glands) is a chronic inflammatory skin condition that is also known as acne inversa and, historically, as Verneuil’s disease. […] Estimates of the prevalence of HS have varied, ranging from less than 1 percent to 4 percent. Prevalence in the United Kingdom from a study using the nationwide Clinical Practice Research Datalink (CPRD), which also identified undiagnosed people with HS, was 0.77 percent. Another population-based study that utilized data from a database of more than 48 million patients in the United States found an incidence of 11.4 per 100,000 population.

• #3 Hidradenitis Suppurativa: An Interdisciplinary Problem in Dermatology, Gynecology, and Surgery—Pathogenesis, Comorbidities, and Current Treatments

  https://www.mdpi.com/2075-1729/13/9/1895

  This persistent inflammatory disease has a significant impact on quality of life, causing patients to experience social stigma, poor mental health, and higher suicide rates compared to the general public. […] The issue discussed in this paper constitutes a niche, as it is an undeveloped area of research. Searching the PubMed database using keywords related to HS in gynecology returned only 38 records, which gives the impression that this serious clinical problem is underestimated. […] Most authors agree that HS is a debilitating disorder characterized by chronic inflammation in intertriginous areas with an often-unsatisfactory response to treatment. […] Based on our observations, a phenomenon that worsens the prognosis further is the late diagnosis, which was confirmed by the work of Howdhury et al.

• #4 Hidradenitis suppurativa across the globe | CCID

  https://www.dovepress.com/incidence-risk-factors-and-prognosis-of-hidradenitis-suppurativa-acros-peer-reviewed-fulltext-article-CCID

  Hidradenitis suppurativa, a chronic inflammatory disease of the skin, affects a patients quality of life to a greater extent. While the disease burden, including its incidence and prevalence, has been extensively studied in the western population, there is a paucity of data from developing countries on the epidemiology of Hidradenitis suppurativa. […] The estimated global prevalence of Hidradenitis suppurativa is found to be 0.00033 4.1%, with a relatively higher prevalence of 0.7 1.2% in European and US populations. […] Overall, the prevalence of HS remains uncertain. However, utilization of large databases may help epidemiologists with the precision of existing estimates. […] While the epidemiology of HS may be well established in Western countries such as the United States of America (USA) and Europe, Hidradenitis suppurativa needs to be explored in other countries of the world, especially non-western populations.

• #5

  https://www.ghisa.org/en/hidradenitis-suppurativa/the-prevalence-of-hidradenitis-suppurativa

  There is wide variation in incidence and prevalence figures available from HS epidemiology studies performed prior to the Global Hidradenitis Suppurativa Atlas (GHiSA) initiative, which was one of the drivers for conducting a unified global prevalence study. Prevalence estimates have varied from 0.05% to 4.1%, representing an 82-fold difference. […] A primary care database study from the UK found an HS prevalence of 0.54% in diagnosed patients, which increased to 0.77% with the inclusion of validated undiagnosed cases with a history of multiple attendances for flexural skin boils. […] Questionnaire-based studies from mainland Europe tend to produce higher prevalence figures. A cross-sectional study of 10,000 members of the French population, with a 69% response rate, provided a one-year period prevalence of 0.97% based on responses to a survey question about painful flexural boils.

• #6 An Update on Hidradenitis Suppurativa (Part I): Epidemiology, Clinical Aspects, and Definition of Disease Severity | Actas Dermo-Sifiliográficas

  https://actasdermo.org/en-an-update-on-hidradenitis-suppurativa-articulo-S1578219015002437

  Hidradenitis suppurativa is a chronic inflammatory disorder that has attracted increasing attention in recent years due to underestimations of prevalence and the considerable impact of the condition on interpersonal relationships, physical appearance, self-esteem, and body image. […] Most epidemiological studies of HS have been conducted in Europe and the United States. The epidemiological data presented in this section are based on estimates for these populations, as we found no data for Spain in our review of the literature. […] Prevalence figures for HS vary widely across the literature, probably because of differences in populations and methodologies. Numerous studies cite prevalence rates of between 1% and 4% based on the work of Jemec et al., who calculated a 1-year prevalence of 1% and a point prevalence of 4.1% in the Danish population in the 1990s.

• #7 Hidradenitis Suppurativa: An Interdisciplinary Problem in Dermatology, Gynecology, and Surgery—Pathogenesis, Comorbidities, and Current Treatments

  https://www.mdpi.com/2075-1729/13/9/1895

  Hidradenitis suppurativa (HS) has an estimated global prevalence of 0.00033–4.1% and it disproportionately affects females compared to males. […] The prevalence of HS varies globally, ranging from 0.00033% to 4.1%. Recent studies reported a prevalence of 0.7–1.2% in the US and European populations, though it is rare in Poland, occurring at a rate of just 0.001%. […] In 2021, Abdulhadi et al. conducted a systematic review and meta-regression analysis involving 16 quantitatively assessed studies. Their research revealed that the overall prevalence of Hidradenitis suppurativa was determined to be 0.40%. […] Female sufferers outnumber males at a ratio of 3:1 in Caucasian populations, with the disease occurring most commonly in the third and fourth decades of life. […] Unfortunately, the average time between disease onset and diagnosis is 7–10 years.

• #8

  https://link.springer.com/article/10.1007/s13671-022-00372-7

  This review aimed to provide a comprehensive and current state of art about epidemiology and clinical aspects of the HS. […] Our search yielded 17 articles that included studies that showed a prevalence range from 0.00033 to 1.4%. Incidence data is limited. HS is more prevalent in women than in men. The highest prevalence is found in the third and fourth decade of life. […] In Europe, HS prevalence ranges from 0.001 to 1.4%. The lowest prevalence is reported for the Polish population and Ireland has the highest prevalence. […] In Australia, a population-based cross-sectional study estimated a prevalence of 0.67%. […] Among the articles included, only the study by Kirsten et al. included HS new cases data. An incidence in the German population of 0.03% was estimated. […] The age range where HS is most frequently found worldwide is between 15 and 40 years, with a higher prevalence in the third and fourth decades of life.

• #9 Epidemiology of Hidradenitis Suppurativa: Current Status | springermedizin.de

  https://www.springermedizin.de/epidemiology-of-hidradenitis-suppurativa-current-status/23591366

  Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease characterized by occlusion of hair follicles as a primary pathogenic factor. It affects areas of the body with apocrine glands, predominantly in the axillary, inguinal, intermammary, and anogenital regions. Clinically, its manifestations vary from inflammatory nodules and abscesses to the formation of sinus tracts and scarring. HS is more prevalent in women than in men. The highest prevalence is found in the third and fourth decade of life. The most frequent localizations are the inguinal, axillary, and perianal regions. There are associations between HS and obesity (OR 2.09), hypertension (OR 1.84), and dyslipidemia (OR 4.06), among others. […] In Europe, HS prevalence ranges from 0.001 to 1.4%. The lowest prevalence is reported for the Polish population and Ireland has the highest prevalence. In France, a study determined the prevalence of the most common dermatological disorders in the French population in a period of 12 months, finding a prevalence of 0.97%. Kirsten et al. calculated a period prevalence between 2010 and 2015 in Germany. This study included a sample of 2.3 million insured people, which is equivalent to 40% of the country’s insured population, calculated a prevalence of 0.04%. A Polish study carried out by Matusiak et al. including almost 90% of the country’s population, calculated an estimated prevalence for HS of 0.001%. In Italy, Bettoli et al. reported an analysis of the possible variations between two consecutive Italian registries of patients with HS between the years 2009 and 2013 vs. 2015-2019 concluding that the disease frequency estimates ranged between 5:10,000 and 4:100 people. Finally, in Ireland, a cross-sectional study was carried out in 4 selected hospitals, in which the prevalence of the disease was estimated at 1.4%.

• #10 Hidradenitis Suppurativa (HS) prevalence, demographics and management pathways in Australia: A population-based cross-sectional study | PLOS One

  https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0200683

  Hidradenitis Suppurativa (HS) is a painful, chronic inflammatory skin disease. Global estimates of prevalence vary between 0.03% and 4% of the population. Our main aim was to determine HS prevalence in the Australian adult population focussing on the demographics, management pathways and diagnosis rate of individuals living with HS. 11,433 Australian residents answered the HS questionnaire, 88 screening positive for HS (0.77%; 95% CI 0.620.95). Considering the previously reported sensitivity (0.97) and positive predictive value (0.85) of the screening questionnaire, HS prevalence was estimated to be 0.67% (95% CI 0.53%-0.84%). The diagnosis rate amongst the suspected HS cases was low, which appeared to be due to a combination of patients not seeking help and decentralization of care. Individuals suspected of having HS were more likely to be females, young, obese, smokers, unemployed or at home duties and having lower annual personal income in comparison with individuals not suspected of having HS. Based on face-to-face household interviews of a large (N = 11,433) representative sample of the adult Australian population using a previously validated HS screening questionnaire, the prevalence of HS in Australia was estimated to be 0.67% (95% CI 0.53%-0.84%) after adjusting for the previously reported sensitivity and positive predictive value of the screening questionnaire. The diagnosis rate among the individuals who screened positive for HS was low, with only 6 out of the 88 individuals identified through the HS screening questionnaire having reported a previous diagnosis of HS or acne inversa (6.8%; 95% CI 3.2% to 14.1%).

• #11

  https://journals.lww.com/ijdv/fulltext/2022/03000/prevalence_of_acne_inversa__hidradenitis.1.aspx

  This study was performed to estimate the prevalence of hidradenitis suppurativa (HS) in China and describe the demographic and clinical features of HS in the Chinese population. […] The prevalence of HS was calculated as the percentage of patients with HS among all visitors at participating clinics during the 1-month study period. […] We identified 92 patients with HS among 274,742 visitors at participating clinics. The prevalence rate was 0.03349% or 33.49 per 100,000 population (95% confidence interval, 26.64-40.32), and the female:male ratio was 1.0:4.7. […] The overall prevalence of HS in China was lower than that in Western and other Asian countries with a predominance of male patients. […] The estimated prevalence of HS varies greatly, ranging from 0.00033% to 4.1%; a prevalence of 0.7% to 1.2% was recently reported in United States and European populations.

• #12

  https://journals.lww.com/ijdv/fulltext/2022/03000/prevalence_of_acne_inversa__hidradenitis.1.aspx

  A study using national health insurance claims data in Korea revealed a prevalence of 0.06%, which is much lower than that reported in Western countries. […] To our knowledge, no data on the epidemiology of HS in the Chinese population are available. […] This is the first epidemiological study on the prevalence of HS in China, which was found to be lower than that reported in Western countries and even some Asian countries like South Korea. […] The prevalence of HS among dermatology clinic visitors was 33.49 (95% CI, 26.64-40.32) per 100,000 population. […] The prevalence rate in southern China was slightly higher than that in northern China, but the difference was not statistically significant (P 0.05). […] The highest prevalence was found in the 16- to 19-year age group (62.72 per 100,000) followed by 20- to 29-year age group (60.09 per 100,000). […] The anatomical distribution of HS lesions commonly includes the axillae, groin, buttocks, and perineal and perianal regions as reported in previous Western and Asian studies. […] The study provides valuable information on the state of HS in China and calls for further research.

• #13 Epidemiology of Hidradenitis Suppurativa: Current Status | springermedizin.de

  https://www.springermedizin.de/epidemiology-of-hidradenitis-suppurativa-current-status/23591366

  In Korea, Lee et al. obtained data from the national health insurance database from 2007 to 2016, finding 28,516 patients diagnosed with HS, and taking into account an estimated population of 50 million, it was determined a prevalence of 0.06%. […] In Australia, a population-based cross-sectional study estimated a prevalence of 0.67%. […] Among the articles included, only the study by Kirsten et al. included HS new cases data. An incidence in the German population of 0.03% was estimated. […] Hidradenitis suppurativa is a complex dermatological disorder with a worldwide distribution. The age of onset, gender, clinical classification, and anatomical location is globally similar with very few exceptions. The identification of risk factors and comorbidities associated has allowed for a better understanding of the disease and thus a more efficacious treatment.

• #14 Hidradenitis suppurativa across the globe | CCID

  https://www.dovepress.com/incidence-risk-factors-and-prognosis-of-hidradenitis-suppurativa-acros-peer-reviewed-fulltext-article-CCID

  Consequently, researchers and clinicians are not aware of the burden of HS, its risk factors, incidence or prevalence, and its prognosis in developing countries. […] Given the lack of literature on the epidemiology of HS from developing countries, we undertook a review of different domains of epidemiology such as prevalence, incidence, risk factors, outcomes, prognostic factors, and distribution across the globe. […] According to various studies conducted across the globe, the prevalence of HS varies across different countries, depending upon the type of population, methods to collect data, and data sources used. […] However, the most recent data from western countries, such as USA and Norway, reveal a surge in the incidence of the disease compared to the past years. […] The prevalence and incidence in Germany was reported to be 0.03%.

• #15 The epidemiology of hidradenitis suppurativa – PubMed

  https://pubmed.ncbi.nlm.nih.gov/32880911/

  Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease defined clinically by multiple, painful inflammatory lesions occurring predominantly in flexural sites. Onset is typically soon after puberty; however, it remains unknown whether the menopause induces remission. In North American and European patients with HS the female-to-male ratio is approximately 3 : 1 but the ratio is 1 : 2 in South Korean patients. It may be that some elements of HS epidemiology cannot be generalized across all populations. Elements of HS epidemiology in the USA and Europe are well established, including strong associations with obesity and smoking, which may increase disease severity. There are associations between HS and other cardiovascular disease (CVD) risk factors, including type 2 diabetes and metabolic syndrome. People with HS have double the risk of death from CVD compared with those without HS and 15 times the risk compared with patients with psoriasis.

• #16 An Update on Hidradenitis Suppurativa (Part I): Epidemiology, Clinical Aspects, and Definition of Disease Severity | Actas Dermo-Sifiliográficas

  https://actasdermo.org/en-an-update-on-hidradenitis-suppurativa-articulo-S1578219015002437

  The only population-based study to investigate the prevalence of HS (conducted in the US state of Minnesota) reported an estimated prevalence of 0.13%, which was considerably lower than previous estimates. […] HS appears to be more common in women. According to the literature, the male to female ratio is approximately 3:1, with some of the more relevant studies reporting values in the range of 2.6:1 to 3.3:1. […] Very few studies have analyzed the distribution of HS by race or ethnicity, and objective data are scarce in this area. One recent study of the US population reported that HS was more common in black individuals. […] Epidemiologically, HS has been associated with multiple comorbidities, which are summarized in Table 1.

• #17 Hidradenitis suppurativa – Symptoms and causes – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/hidradenitis-suppurativa/symptoms-causes/syc-20352306

  Hidradenitis suppurativa tends to start after puberty, usually before age 40. It can persist for many years and worsen over time. […] Women are three times more likely to develop hidradenitis suppurativa, though this ratio can differ by location around the world. Also, Black people are more likely to develop this disease than people of other races. This could be attributed to genetic factors. […] The risk of hidradenitis suppurativa is higher for people in their teens and 20s. […] Ethnicity or race might affect risk level. The condition occurs most in Black people, possibly due to genetic factors. […] A tendency to develop hidradenitis suppurativa can be inherited. […] Hidradenitis suppurativa is more common and severe in people who are overweight. It also has an association with severe acne, arthritis, diabetes, metabolic syndrome and inflammatory bowel disease. […] Smoking tobacco has been linked to hidradenitis suppurativa. […] Goldburg BA, et al. Hidradenitis suppurativa: Epidemiology, clinical presentation, and pathogenesis. Journal of the American Academy of Dermatology. 2020; doi: 10.1016/j.jaad.2019.08.090.

• #18 Hidradenitis Suppurativa: Practice Essentials, Pathophysiology, Etiology

  https://emedicine.medscape.com/article/1073117-overview

  In the United States, the prevalence of HS appears to be 1-2% in the general population. […] Worldwide, the prevalence of hidradenitis suppurativa appears to be 1% of the general population; it was 4% in a group of young adults who were treated at a clinic for sexually transmitted diseases. […] A 2008 study showed that the prevalence among persons aged 55 years and older was significantly lower than that in younger age groups (0.5% vs 1.4%). […] In the great majority of cases, the onset of HS comes between the ages of 11 and 50 years (average patient age, 23 y); it comes before age 11 years in fewer than 2% of cases. […] Although HS is widely considered to occur more frequently in females than in males, with a ratio as high as 2-5:1, reports on sex prevalence have been controversial. […] Most authors report no specific racial predilection. One report suggested an increased observed incidence in Blacks, possibly because Blacks have a greater density of apocrine glands than Whites do.

• #19 Hidradenitis Suppurativa – EHSF e.V.

  https://ehsf.eu/hidradenitis-suppurativa/

  The reported prevalence of HS in older studies ranged widely from 0.03 to 4%. Women are more commonly affected; the male-female ratio is 1:2.7 to 1:3.3. […] HS seems to develop rarely before puberty or after menopause, although the persistence of existing lesions after menopause is not unusual. It was reported that only 2% of cases occur before the age of 11 years. The average age at onset is 23 years. […] For such a chronic, debilitating disease, efficient screening of the population in primary care setting to early detect possible HS cases is essential, in order to facilitate early referral. This is reflected in the current long mean time to diagnosis of 7 years. Since HS lacks a specific test, implementation of criteria to be used both in primary care setting and by dermatologists, is of high significance.

• #20 Alt… – Journal of the American Academy of Dermatology (JAAD)FacebookShared with Public

  https://www.facebook.com/JAADjournals/posts/although-many-patients-across-all-ages-sexes-and-races-may-suffer-from-hidradeni/977128971111779/

  Although many patients across all ages, sexes, and races may suffer from hidradenitis suppurativa (HS), there are certain subgroups that appear to be disproportionately affected. The highest standardized prevalence of HS has been found to occur in patients aged 18-39 years, and standardized prevalence of HS in women is more than twice that in men. In the United States, HS disproportionately affects Black patients who have 3 times higher standardized prevalence compared to Caucasians. […] Hidradenitis suppurativa (HS) is a chronic, inflammatory condition predominantly affecting younger adults and disproportionately affecting women and Black Americans. Estimated prevalences vary significantly according to study methodology; however, true prevalence may range from approximately 0.1% to…

• #21 Hidradenitis Suppurativa: Rapid Evidence Review | AAFP

  https://www.aafp.org/pubs/afp/issues/2019/1101/p562.html

  Hidradenitis suppurativa is a chronic folliculitis affecting intertriginous areas. Onset generally occurs in young adulthood to middle adulthood (18 to 39 years of age). Females and blacks are more than twice as likely to be affected. Additional risk factors include family history, smoking, and obesity. […] The prevalence of hidradenitis suppurativa in the United States is approximately 0.1%, with increasing incidence over the past 10 years. Onset of hidradenitis suppurativa occurs in young adulthood to middle adulthood (18 to 39 years of age). Nonmodifiable risk factors include family history, female sex (incidence of 16.1 and 6.8 per 100,000 for females and males, respectively), and black race (incidence of 30.6 and 11.7 per 100,000 in blacks and whites, respectively). Modifiable risk factors include cigarette smoking and obesity. Hidradenitis suppurativa is associated with several systemic conditions, including diabetes mellitus and Crohn disease.

• #22 What is Hidradenitis Suppurativa (HS)?

  https://www.hsdiseasesource.com/what-is-hs

  A population-based analysis of HS found that HS disproportionately affects African American patients up to 3 times more than Caucasian patients. […] However, HS can occur in people of all ethnicities. […] Up to 40% of patients report a family history of HS. HS seems to develop in genetically predisposed individuals whose immune system elicits an abnormal chronic inflammatory response.

• #23 Hidradenitis suppurativa across the globe | CCID

  https://www.dovepress.com/incidence-risk-factors-and-prognosis-of-hidradenitis-suppurativa-acros-peer-reviewed-fulltext-article-CCID

  Generally, the prevalence of HS is higher in western countries such as the USA, UK, Denmark, and Norway than in non-western countries such as Japan, Korea, and Taiwan. […] The existing literature provides a wide evidence base to advance our understanding of the risk factors associated with HS. […] The literature suggests that 7089% of the patients with Hidradenitis suppurativa are smokers, indicating that tobacco is a triggering factor for HS. […] The association between obesity and HS can be explained by many ways. […] Hidradenitis suppurativa can lead to substantial complications such as squamous cell carcinoma, with a higher ratio in males than females. […] The findings of a retrospective study (n=200) demonstrated that patients with Hidradenitis suppurativa had a 50% more risk of the incidence of malignancy.

• #24 Hidradenitis Suppurativa Patient Guide

  https://hspatientguide.com/guide/hidradenitis-suppurativa-overview/

  HS is most common in people in their 20s and 30s. Women tend to develop HS earlier than men, possibly due to their earlier onset of puberty. Some studies have shown that a certain subset of people develop HS before the age of 18, which is considered early onset. People may also develop the disease later in their life, after the age of 40, which is considered late onset. […] There are risk factors that are non-modifiable, which means they are inherent traits you cannot change. There are also risk factors that are modifiable, which means they can be changed with lifestyle choices. Non-modifiable risk factors for HS include family history and genetics. Modifiable risk factors include smoking, obesity, skin friction, and diet.

• #25

  https://journals.lww.com/greenjournal/fulltext/2021/04000/clinical_epidemiology_and_management_of.27.aspx

  Hidradenitis suppurativa is a chronic immune-mediated inflammatory skin disease with a prevalence of 0.11%, characterized by nodules and abscesses in the axillae, groin, and inframammary areas, sometimes developing into tunnels (or fistulas) and scars. […] The most comprehensive prevalence estimates in the United States and United Kingdom range from 0.1% to 1%. Most patients are aged 18-40 years. The standardized point prevalence in U.S. women is approximately 2.4-fold higher than in men and 3-fold higher among Black patients than White patients. Increased body mass index (BMI, calculated as weight in kilograms divided by height in meters squared) is positively associated with presence and severity of hidradenitis suppurativa, and smoking tobacco is a risk factor. […] As a chronic inflammatory disease, hidradenitis suppurativa exemplifies the link between integumentary and comorbid systemic disease through shared inflammatory pathways. Patients have double the comorbidity burden compared with the general population, and hidradenitis suppurativa has independent associations with several individual comorbid diseases. Polycystic ovarian syndrome (PCOS) prevalence among women with hidradenitis suppurativa is 9.0%, approximately twice the independent odds for patients who do not have hidradenitis suppurativa.

• #26

  https://journals.lww.com/greenjournal/fulltext/2021/04000/clinical_epidemiology_and_management_of.27.aspx

  The most frequent, and perhaps most severe, comorbidities in hidradenitis suppurativa are psychiatric. Depression prevalence is estimated to be as high as 43%. Suicidal ideation or attempt has been reported in 12% of patients, who tragically demonstrate increased rates of completed suicide, particularly among women.

• #27 Hidradenitis suppurativa and acne vulgaris and conglobata—systematic review and meta-analysis | Biomedical Dermatology | Full Text

  https://biomeddermatol.biomedcentral.com/articles/10.1186/s41702-019-0045-z

  Hidradenitis suppurativa (HS) is a chronic inflammatory skin disorder which involves painful nodules and draining abscesses in flexural areas. […] Given that follicular obstruction, dilatation and inflammation feature in both HS and acne vulgaris/conglobata, it has been suggested that HS is associated with acne vulgaris/conglobata. […] From pooled unadjusted meta-analysis, we found a significantly higher proportion of patients with acne vulgaris/conglobata in HS cases compared to controls (OR 3.44, 95% CI 1.956.07, P0.0001, I2=100%). […] Pooled meta-analysis was also performed with adjusted effect sizes. This demonstrated that HS was significantly associated with acne vulgaris/conglobata after adjustment for potential confounders (OR 3.44, 95% CI 2.434.87, P0.00001, I2=99%). […] In summary, a significant association was found between HS and acne vulgaris/conglobata. This has implications in terms of understanding the burden of disease on patient quality of life as well as consideration of optimal management strategies to target both disorders. Physicians taking care of patients with HS should be aware of this association.

• #28 Hidradenitis Suppurativa | IntechOpen

  https://www.intechopen.com/online-first/1198287

  The progression of HS has been linked to squamous cell carcinoma (SCC) development. […] Enhancing understanding of HS will benefit practitioners across various medical specialties, particularly those in primary care, gynecology, oncology, emergency medicine, surgery, and psychiatry, who are likely to encounter this condition. […] A variety of factors contribute to HS pathogenesis, including a range of hormonal, genetic, dietary, and mechanical influences. […] The Hurley Staging System is widely used to classify HS severity based on morphology, distribution, and chronicity. […] Lowered quality of life (QoL) has been well-established among patients with HS. […] Effective management of hidradenitis suppurativa (HS) begins with early detection and implementation of lifestyle modifications aimed at preventing the formation of new lesions and mitigating the exacerbation of subcutaneous inflammatory processes.

• #29

  https://link.springer.com/article/10.1007/s13671-022-00372-7

  In most studies, it is observed that HS can be twice more prevalent in women than in men. […] Shlyankevich et al. report the association of comorbidities within patients with HS, obesity (OR 2.09), hypertension (OR 1.84), dyslipidemia (OR 4.06), thyroid disease (OR 2.18), psychiatric disease (OR 3.95), arthropathy (OR 9.41), and polycystic ovary syndrome (OR 13.7).

• #30 Hidradenitis Suppurativa: Symptoms and Treatment | Doctor

  https://patient.info/doctor/hidradenitis-suppurativa-pro

  The prevalence in Europe has been estimated to be in the region of 1%. Overall it occurs more often in women. Submammary, axillary and inguinal involvement is more common in females but perineal involvement is more common in men. It does not start before puberty. Hormonal factors are thought to play a role. Average age of onset is 21 years. Hidradenitis suppurativa is more common in Afro-Caribbean populations and is rare in people from Asia. […] Hidradenitis suppurativa can be divided into the following three clinical stages (Hurley’s classification): Stage I: abscess formation, single or multiple without sinus tracts and scarring. Stage II: recurrent abscesses with sinus tracts and scarring; single or multiple widely separated lesions. Stage III: diffuse or almost diffuse involvement or multiple interconnected tracts and abscesses. […] Recurrence rate tends to be high with many treatment options. The quality of data on recurrence after wide excision is poor but some evidence suggests lower recurrence rates with wide excision where skin flaps or skin grafts are used as the closure methods.

• #31 Hidradenitis Suppurativa (HS) | HS Awareness | HCP

  https://www.hs-awareness.com/about-hs

  In the United States, approximately 1 in 100 people may have HS and many go undiagnosed. The average time to diagnosis is up to 10 YEARS. 7 in 10 patients may have moderate or severe HS by the time they receive a diagnosis. Patients may see up to 10 providers before receiving an accurate diagnosis. […] HS is widely under-recognized. This can cause diagnostic delays that can facilitate disease progression and long-lasting negative effects on a patient’s quality of life. […] Knowing some of the common risk factors and comorbidities associated with HS can help identify patients early on. Some risk factors may also be comorbidities. […] Given the numerous comorbidities associated with HS, management coordinated between a multidisciplinary care team should be based on the individual.

• #32

  https://www.ilds.org/news-events/news/first-hs-report-launched/

  Offers first globally comparable data on the epidemiology of HS. […] The report offers a comprehensive overview of HS and explores the gaps, barriers, and issues limiting a greater understanding of its global epidemiology. […] GHiSA seeks to improve the management of HS through global collaboration and research and to provide epidemiological insights that pave the way for enhanced global healthcare interventions. […] HS is a high-impact disease yet one that is under-recognised, frequently misdiagnosed and, as a result, neglected.

• #33

  https://revista.spdv.com.pt/index.php/spdv/article/view/835

  Revuz JE, Canoui-Poitrine F, Wolkenstein P, Viallette C, Gabison G, Pouget F, et al. Prevalence and factors associated with hidradenitis suppurativa: results from two case-control studies. J Am Acad Dermatol. 2008;59:596-601. […] Jemec GB, Heidenheim M, Nielsen NH. The prevalence of hidradenitis suppurativa and its potential precursor lesions. J Am Acad Dermatol. 1996;35:191-4. […] Santos JV, Lisboa C, Lanna C, Costa-Pereira A, Freitas A. Is the prevalence of hidradenitis suppurativa being overestimated in Europe? Or is the disease underdiagnosed? Evidence from a nationwide study across Portuguese public hospitals. Int J Dermatol. 2017;56:1491-2. […] Crowley JJ, Mekkes JR, Zouboulis CC, Scheinfeld N, Kimball A, Sundaram M, et al. Association of hidradenitis suppurativa disease severity with increased risk for systemic comorbidities. Br J Dermatol. 2014;171:15615. […] Onderdijk AJ, van der Zee HH, Esmann S, Lophaven S, Dufour DN, Jemec GB, et al. Depression in patients with hidradenitis suppurativa. J Eur Acad Dermatol Venereol 2013;27:473-8.

• #34 Hidradenitis suppurativa across the globe | CCID

  https://www.dovepress.com/incidence-risk-factors-and-prognosis-of-hidradenitis-suppurativa-acros-peer-reviewed-fulltext-article-CCID

  HS is associated with a myriad of comorbidities. […] This general literature review provides a comprehensive overview of the epidemiology of Hidradenitis suppurativa, including prevalence, incidence, risk factors, complications, associated comorbid, prognosis, and quality of life. […] Since the disease tends to be under recognized, future studies should rely on clinical diagnosis rather than self-reporting to avoid the potential of recall bias. Attention needs to be diverted to developing countries with less amount of data on Hidradenitis suppurativa.

• #35 An Update on Current Clinical Management and Emerging Treatments in Hidradenitis Suppurativa

  https://www.skintherapyletter.com/hidradenitis-suppurativa/emerging-treatments-update/

  Hidradenitis suppurativa (HS) is a severe, debilitating, chronic inflammatory skin disease characterized by recurrent painful nodules, abscesses and draining sinus tracts. […] While an estimated 1% prevalence rate is often described in literature, HS is thought to be widely underdiagnosed. […] The onset of HS typically occurs between ages 20-40 years with a 3:1 predilection for women over men and higher rates among those of African descent. […] There is a strong psychosocial impact of the condition, with HS patients reporting high rates of depression, anxiety, social stigmatization, and shame leading to significant reductions in quality of life. […] The management of HS is a challenge, in part due to its chronic and variable nature with a poorly understood pathophysiology. […] In addition to its painful dermatologic implications, HS is associated with many comorbidities including inflammatory bowel disease, psoriasis, and metabolic syndromes, as well as significant mental health burden with increased depression, anxiety and suicide rates observed.

• #36 Hidradenitis Suppurativa (Acne Inversa): A Complete Picture – DermNet

  https://dermnetnz.org/topics/hidradenitis-suppurativa

  Hidradenitis suppurativa often starts at puberty, is most active between the ages of 20 and 40 years, and in women can resolve at menopause. It is three times more common in females than in males. Associations and risk factors include: […] Hidradenitis developing at a young age in childhood or early adolescence may be an indicator of underlying precocious puberty. […] The Hurley system, the most widely used assessment tool, describes three clinical stages. […] Hidradenitis suppurativa tends to improve in pregnancy in those who usually have flares during menstruation. Normal vaginal delivery is possible unless the patient has extensive painful genital lesions. […] HS is a chronic scarring condition. Spontaneous remission may occur with time, but scarring persists. […] Early diagnosis and treatment are required to minimise lasting damage.

• #37 Hidradenitis suppurativa: Epidemiology and scope of the problem.

  https://research.bidmc.org/alexa-kimball/publications/hidradenitis-suppurativa-epidemiology-and-scope-problem

  Hidradenitis suppurativa (HS) is a chronic inflammatory disease involving painful, deep abscesses and chronic, draining sinus tracts. […] Widespread causes and effects of HS are difficult to determine because the prevalence is dependent on a variety of things, including how and where data are collected, resulting in significant bias. […] The exact prevalence of HS remains unknown because of the difficulty in collecting and extrapolating data and the usefulness of studies; however, high comorbidity and disease severity is observed, resulting in increased hospital visits for patients with HS nearly double that of other diseases. […] This article will address the epidemiology of HS through current available research.

• #38 Hidradenitis suppurativa – Management, comorbidities and monitoring

  https://www.racgp.org.au/afp/2017/august/hidradenitis-suppurativa-management-comorbidities

  Hidradenitis suppurativa (HS) is a chronic inflammatory disease that occurs in the intertriginous areas of the body and is characterised by multiple inflammatory nodules, abscess and fistulas appearing in flares and resulting in scarring. […] The current estimate of HS incidence in the general Australian population is 0.67%, with women more frequently affected than men (ratio 3:1). […] Failure to recognise HS by healthcare professionals has resulted in misdiagnosis and mismanagement of many patients, who may present to a variety of healthcare providers. These patients often undergo repeat and unnecessary investigations and procedures; for example, the misdiagnosis of recurrent boils is often followed by inappropriate surgery and antibiotic therapy. This results in substantial financial burden for the patient and healthcare system.

• #39 Hidradenitis Suppurativa: An Interdisciplinary Problem in Dermatology, Gynecology, and Surgery—Pathogenesis, Comorbidities, and Current Treatments

  https://www.mdpi.com/2075-1729/13/9/1895

  According to other studies, it is probably even more important to attempt to understand the pathomechanisms of the disease, which would make healthcare providers and patients more aware of HS-associated risks and allow for the introduction of an appropriate treatment scheme. […] It should be strongly underlined that females affected by HS should receive holistic and interdisciplinary care involving gynecologists, dermatologists, endocrinologists, radiologists, and surgeons.

• #40 Management of hidradenitis suppurativa: an Australasian consensus statement

  https://dermnetnz.org/topics/hidradenitis-suppurativa-guidelines

  Hidradenitis suppurativa (HS) is a debilitating and distressing chronic inflammatory skin disease affecting about one in every 150 Australians. […] HS most frequently develops in early adulthood, and onset before puberty or, in women, after menopause, is rare. […] Estimates of prevalence range from 0.1% or less to more than 4%, reflecting variation in the settings of studies, methods of ascertainment and diagnostic criteria applied. […] In face-to-face interviews with 11,433 adult Australian residents using a validated HS screening question, the prevalence of HS was estimated at 0.67%. […] Despite the scarcity of high-quality evidence to guide treatment, positive outcomes can be achieved with existing therapies, although better information is needed to guide their initial selection, combination and sequencing. […] Further efforts are required to educate healthcare professionals and the general public about HS, and to encourage research on its epidemiology and pathophysiology.

Zobacz więcej